Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06183931 · ClinicalTrials.gov registry record · Phase 3
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
A Phase 3 study of Transthyretin Amyloid Cardiomyopathy, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,181
- Enrollment target
- 20
- Study locations
NCT06183931 is a Phase 3 study of Transthyretin Amyloid Cardiomyopathy that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 1,181 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT06183931, a Phase 3 study of Transthyretin Amyloid Cardiomyopathy, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,181 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN2220
Study Locations (20)
California
- Research Site - Irvine
- Research Site - La Jolla
- Research Site - Palo Alto
- Research Site - San Francisco
New York
- Research Site - New York
- Research Site - New York
- Research Site - Stony Brook
Florida
- Research Site - Jacksonville
- Research Site - Weston
Georgia
- Research Site - Atlanta
- Research Site - Atlanta
Massachusetts
- Research Site - Boston
- Research Site - Boston
Missouri
- Research Site - Kansas City
- Research Site - St Louis
Colorado
- Research Site - Aurora
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,181 participants |
| Start Date | 2024-01-11 |
| Est. Completion | 2027-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06183931
The ClinicalTrials.gov registry entry for NCT06183931 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloid Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06183931 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06183931 about?
NCT06183931 is a clinical study titled "Study of ALXN2220 Versus Placebo in Adults With ATTR-CM". The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events...
What is the current status of trial NCT06183931?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,181 participants. The study started on 2024-01-11. Estimated completion is 2027-10-05.
What conditions does trial NCT06183931 study?
This clinical trial studies the following conditions: Transthyretin Amyloid Cardiomyopathy.
What interventions are being tested in trial NCT06183931?
The interventions under investigation include: Placebo (DRUG), ALXN2220 (DRUG).
Who is sponsoring clinical trial NCT06183931?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06183931 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloid Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.